These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38617221)

  • 21. Highly specific SARS-CoV-2 main protease (M
    Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E
    Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
    Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
    Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model.
    Kang BM; Kim D; Kim J; Baek K; Park S; Shin HE; Lee MH; Kim M; Kim S; Lee Y; Kwon HJ
    Biomol Ther (Seoul); 2024 Jul; 32(4):481-491. PubMed ID: 38835145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive study of SARS-CoV-2 main protease (M
    Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
    bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
    Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
    ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamical Nonequilibrium Molecular Dynamics Simulations Identify Allosteric Sites and Positions Associated with Drug Resistance in the SARS-CoV-2 Main Protease.
    Chan HTH; Oliveira ASF; Schofield CJ; Mulholland AJ; Duarte F
    JACS Au; 2023 Jun; 3(6):1767-1774. PubMed ID: 37384148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of
    Tong X; Keung W; Arnold LD; Stevens LJ; Pruijssers AJ; Kook S; Lopatin U; Denison M; Kwong AD
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0084023. PubMed ID: 37800975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Miniaturized Modular Click Chemistry-enabled Rapid Discovery of Unique SARS-CoV-2 M
    Yang M; Lee MK; Gao S; Song L; Jang HY; Jo I; Yang CC; Sylvester K; Ko C; Wang S; Ye B; Tang K; Li J; Gu M; Müller CE; Sträter N; Liu X; Kim M; Zhan P
    Adv Sci (Weinh); 2024 Nov; 11(43):e2404884. PubMed ID: 39319611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A yeast-based system to study SARS-CoV-2 M
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
    Tan B; Joyce R; Tan H; Hu Y; Wang J
    Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potential allosteric inhibitor of SARS-CoV-2 main protease (M
    Fatima A; Geethakumari AM; Ahmed WS; Biswas KH
    Front Mol Biosci; 2024; 11():1451280. PubMed ID: 39310374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19.
    Bege M; Borbás A
    Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment.
    Abdelnabi R; Jochmans D; Donckers K; Trüeb B; Ebert N; Weynand B; Thiel V; Neyts J
    Nat Commun; 2023 Apr; 14(1):2124. PubMed ID: 37059708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 3CL
    Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
    Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
    Yang KS; Leeuwon SZ; Xu S; Liu WR
    J Med Chem; 2022 Jul; 65(13):8686-8698. PubMed ID: 35731933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms.
    Ramos-Guzmán CA; Andjelkovic M; Zinovjev K; Ruiz-Pernía JJ; Tuñón I
    Chem Sci; 2023 Mar; 14(10):2686-2697. PubMed ID: 36908962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.